scholarly journals Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

2020 ◽  
Author(s):  
Karolina Obońska ◽  
Michał Kasprzak ◽  
Kamila Tymosiak ◽  
Tomasz Fabiszak ◽  
Magdalena Krintus ◽  
...  
Keyword(s):  
Crossover Study ◽  
Low Dose ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cholesterol Concentration ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Preliminary Results ◽  
Randomized Crossover Study

Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states.

1988 ◽  
Vol 34 (12) ◽  
pp. 2456-2459 ◽  
Author(s):  
J S Cohn ◽  
J R McNamara ◽  
E J Schaefer
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Triglyceride ◽  
Lipoprotein Cholesterol ◽  
Cholesterol Concentration ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Plasma Triglyceride Concentration ◽  
Triglyceride Concentration ◽  
Friedewald Formula

Abstract Lipoprotein cholesterol concentrations in plasma are routinely estimated by using the Friedewald formula, whereby very-low-density lipoprotein cholesterol (VLDL-C) is estimated to be one-fifth the plasma triglyceride concentration. Ordinarily, this formula is applied only to plasma sampled from patients in the fasted state. To determine whether lipoprotein cholesterol measurements are altered substantially in plasma sampled from nonfasting subjects, we obtained postprandial blood samples from 22 healthy subjects (nine men, 13 women, ages 22-79 years) fed a fat-rich meal (1 g fat per kilogram body wt.). The plasma triglyceride concentration increased postprandially in all subjects (233 +/- 16% of baseline at 3 h). The mean cholesterol concentration in plasma was essentially unchanged. High-density lipoprotein cholesterol (HDL-C) was significantly decreased (94 +/- 2% at 3 h, P less than 0.001). VLDL-C and low-density lipoprotein cholesterol (LDL-C), estimated by the Friedewald formula, were compared with measurements obtained by modified Lipid Research Clinics (LRC) methodology. As measured by either method, VLDL-C increased and LDL-C decreased significantly after the fat-rich meal. These postprandial changes were significantly greater (P less than 0.01) when estimated by the Friedewald formula than by LRC methodology. We conclude that (a) lipoprotein cholesterol concentrations measured in the fed subject differ significantly from those measured in the fasted subject, and (b) plasma must be obtained after at least a 12-h fast if an individual's risk of coronary heart disease is to be accurately assessed.

Elevation of Low-Density Lipoprotein Cholesterol Concentration with Over-the-Counter Fish Oil Supplementation

2007 ◽  
Vol 41 (7-8) ◽  
pp. 1296-1300 ◽  
Author(s):  
Jennifer M Malinowski ◽  
Kimberly Metka
Keyword(s):  
Fish Oil ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cholesterol Concentration ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Over The Counter ◽  
Epa And Dha ◽  
Fish Oil Supplementation

Objective: To report a case of elevated low-density lipoprotein cholesterol (LDL-C) concentration in a patient taking fish oil supplements for hypertriglyceridemia. Case Summary: A 63-year-old white woman had been taking 2.7 g of eico-sapentaenotc acid (EPA) and docosahexaenoic acid (DHA) daily in 9 g of over-the-counter (OTC) fish oil capsules for triglyceride lowering. Prior to the adverse event, she had baseline fasting triglyceride (TG) and LDL-C concentrations of 278 mg/dL and 106 mg/dL, respectively. After 6 weeks of treatment with fish oil, fasting TG levels decreased by 47.5% (-132 mg/dL) and the LDL-C increased by 75% (+80 mg/dL). Discontinuation of therapy for 6 weeks resulted in TG returning to high concentrations (334 mg/dL; +56 mg/dL change from baseline) and LDL-C decreasing toward baseline (143 mg/dL; +37 mg/dL change from baseline). Discussion: Fish oil, an omega-3 polyunsaturated fatty acid, consists of EPA and DHA. EPA and DHA are thought to inhibit the synthesis of triglycerides in the liver. Type IV dyslipidemic patients may develop increased LDL-C levels while taking fish oil to lower triglycerides due to possible down-regulation of the LDL-C receptor in hepatic cells and formation of larger LDL particles. Use of the Naranjo probability scale indicates a probable relationship between elevations in LDL-C from baseline and initiation of fish oil treatment for hypertriglyceridemia. It is unknown whether any component within this particular product could have contributed to such an unusual elevation in LDL-C. Conclusions: This case documents a much higher LDL-C elevation associated with OTC fish oil supplementation than has been previously identified in the literature. Healthcare providers should be advised that LDL-C levels may increase with use of OTC fish oil and should monitor patients periodically for such elevations. The significance of this Increase on clinical outcomes is not known.

Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis

2009 ◽  
Vol 202 (2) ◽  
pp. 582-588 ◽  
Author(s):  
Tetsuo Shoji ◽  
Sawako Hatsuda ◽  
Shoko Tsuchikura ◽  
Kayo Shinohara ◽  
Eiji Kimoto ◽  
...  
Keyword(s):  
Carotid Atherosclerosis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cholesterol Concentration ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol
Sign in / Sign up

Export Citation Format

Share Document